Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Acquisitions & Divestments: 2020-2022

Historic Change in Acquisitions & Divestments for Apellis Pharmaceuticals (APLS) over the last 2 years, with Dec 2022 value amounting to $125.0 million.

  • Apellis Pharmaceuticals' Change in Acquisitions & Divestments rose 47.04% to $125.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $393.3 million, marking a year-over-year decrease of 6.36%. This contributed to the annual value of $393.3 million for FY2022, which is 6.36% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Acquisitions & Divestments of $125.0 million as of Q4 2022, which was down 0.00% from $125.0 million recorded in Q3 2022.
  • In the past 5 years, Apellis Pharmaceuticals' Change in Acquisitions & Divestments ranged from a high of $312.5 million in Q4 2020 and a low of $25.0 million during Q1 2021.
  • Its 3-year average for Change in Acquisitions & Divestments is $132.8 million, with a median of $125.0 million in 2022.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first plummeted by 72.80% in 2021, then surged by 140.00% in 2022.
  • Quarterly analysis of 3 years shows Apellis Pharmaceuticals' Change in Acquisitions & Divestments stood at $312.5 million in 2020, then tumbled by 72.80% to $85.0 million in 2021, then surged by 47.04% to $125.0 million in 2022.
  • Its Change in Acquisitions & Divestments was $125.0 million in Q4 2022, compared to $125.0 million in Q3 2022 and $83.3 million in Q2 2022.